RNS Number : 0769X
Pharma C Investments PLC
30 December 2021

30 December 2021

Pharma C Investments Plc

("Pharma C" or the "Company")

Board Changes

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on ancillary businesses, announces that Chana Greenberg has ceased to be a director of the Company with immediate effect. The Board would like to thank Chana for leading the Company through the IPO process and its initial phase as a quoted company.

Toby Shillito, currently Chief Business Development Officer, will take over Chana's responsibilities as acting CEO and the Board intend to appoint an additional non-executive director in the early part of 2022.

This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

The Directors of Pharma C Investments plc take responsibility for this announcement.

- Ends -

Pharma C Investments Sharon Segal, Chair
sharon@pharmacinvestments.com

Novum Securities David Coffman / Lucy Bowden Tel:
(AQSE Corporate Adviser) +44 207 399 9429

About Pharma C Investments

Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal

markets with a particular focus on the UK, EU and Israel and will provide capital, strategic insights and operational support. Pharma C is run by cannabis entrepreneurs who understand the unique challenges of the legal cannabis industry and thus can provide invaluable support and expertise for growing companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFLFFDLIVIL